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ontraction versus contracture and
entronuclear  myopathy versus central
art  myopathy in malignant hyperthermia
although  Correia  et  al.  state  that  the  modern  clinical  use
of dantrolene  is  restricted  to  malignant  hyperthermia,  this
drug is  still  employed  in  the  management  of  spasticity.8
Furthermore,  the  maintenance  of  dantrolene  for  24--48  h
after the  initial  treatment  of  HM  crisis  is  important  to  avoidear  Editor,
e read  with  great  interest  the  review  article  by  Cor-
eia et  al.  ‘‘Malignant  hyperthermia:  clinical  and  molecular
spects’’1 (Hipertermia  maligna:  aspectos  moleculares  e
línicos)  and  would  like  to  comment  on  some  aspects.
In  the  section  ‘‘Malignant  hyperthermia’’,  item
‘Contraction to  exposure  to  halothane-caffeine  (TCHC)
est’’, Correia  et  al.  use  the  term  ‘‘contraction’’  instead
f the  original  term  ‘‘contracture’’.  The  test  for  diagnosis
f susceptibility  to  malignant  hyperthermia  (MH)  is  based
n an  abnormal  contracture  response  after  administration
f caffeine/halothane,  and  not  on  the  normal  response  of
uscle contraction  after  electrical  stimulation,  which  is
pplied throughout  the  test  to  prove  viability  of  the  muscle
ragment tested.  Fig.  1  shows  the  difference  between
ontraction and  contracture  in  the  chart  of  a  positive  test  in
 patient  susceptible  to  MH.  Thus,  the  nomenclature  should
e ‘‘contracture  test’’  in  English  and  teste  de  contratura
n Portuguese.2--4
Also  in  this  subsection,  we  emphasize  that  the  cutoff  lev-
ls of  TCHC  cited  correspond  to  values  used  in  the  U.S.  group
f HM  (MHAUS  --  www.mhaus.org) protocol.  Moreover,  the
rotocol  of  the  European  MH  Group  (EMHG  --  www.emhg.org)
iffers from  the  U.S.  one  in  additional  aspects  that  were
ot mentioned,  such  as  the  number  of  fragments  tested  (six
n the  U.S.  and  four  in  the  European  protocol),  halothane
dministration (single  dose  of  3%  in  the  U.S.  and  an  increas-
ng dose  from  0.5%  to  3%  in  the  European  protocol)  and  ﬁnally
he cutoff,  which  is  0.2  g  to  for  halothane  2%  and  0.2  g  for
affeine 2  mm  in  the  European  protocol.5,6
Unlike  that  noted  by  Correia  et  al.,  in  Brazil  the  Cedhima
Center for  the  Study,  Diagnosis  and  Research  for  Malignant
yperthermia), Escola  Paulista  de  Medicina,  Universidade
ederal de  São  Paulo  (UNIFESP)  uses  the  European  MH  group
rotocol for  in  vitro  muscle  contracture  testing  (IVCT).4
In  the  same  section  ‘‘Malignant  hyperthermia’’,  item
‘Treatment’’, Correia  et  al.  include  as  an  indicated  mea-
ure the  ‘‘Replacement  of  anesthesia  circuit  by  other  circuit
ncontaminated by  anesthetic  agent’’.  It  is  important  to
mphasize here  that  there  is  no  indication  for  this  measure
uring the  treatment  of  a  crisis,  but  only  in  the  preparation
f the  anesthetic  machine  for  anesthesia  in  a  patient  with  a
istory of  HM.  At  the  time  of  a  MH  crisis  we  must  ‘‘disconnect
he vaporizer,  but  with  no  waste  of  time  changing  the  cir-
uit or  the  anesthetic  machine’’.7 In  ‘‘Dantrolene’’  item,
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0.5% 1%igure  1  In  vitro  muscle  contracture  test  (IVCT)  in  response
o halothane.  The  two  lower  arrows  indicate  the  time  at  which
he drug  was  added.  The  upper  arrow  indicates  the  lines  that
orrespond to  muscle  contractions  triggered  by  electrical  stim-
lation. The  lateral  double  arrow  indicates  the  ascension  of  the
ase  line,  which  corresponds  to  an  abnormal  muscle  contrac-
ure.
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Figure  2  Cross-sectional  histological  sections  of  striated  muscle  (f
thy:  the  horizontal  arrow  indicates  a  muscle  ﬁber  with  unmarked  c
with  homogeneous  normal  marking;  histochemical  reaction  with  N
with  central  nucleus,  and  black  arrows  show  ﬁbers  with  normal  po
(subsarcolemmal);  hematoxylin  and  eosin  stain.
relapses;  however,  in  a  dosage  of  1  mg/kg  every  4--8  h,  or
continuously at  0.25  mg/kg/h  (or  6  mg/kg/d).9
In  the  section  ‘‘RYANODYNE  RECEPTORS  (RYRs)’’’,  in
‘‘Correlated channelopathies’’  item,  the  term  doenc¸a  do
núcleo central  appears  twice  as  a  translation  of  ‘‘central
core disease’’.  However,  the  suggested  translation  into  Por-
tuguese for  central  core  myopathy  would  be  miopatia  da
parte central  (C05.651.575.300  C10.668.491.550.300),  as
recommended by  the  site  Descriptors  in  Health  Sciences
(http://decs.bvs.br/), under  the  Uniﬁed  Medical  Lan-
Rguage  System  (http://www.nlm.nih.gov/research/umls/).
This  distinction  is  important  because,  among  other  clinical
and mutational  associated  differences,  the  histopathology
is distinct,  as  can  be  seen  in  Fig.  2.  Fig.  2A  depicts  the
appearance of  miopatia  or  doenc¸a  da  parte  central  (cen-
tral core  disease  or  CCD):  There  is  a  central  marking  ﬂaw  in
oxidative histochemical  reactions  (such  as  SDH  and  NADH),
thanks to  the  absence  of  mitochondria.10 On  the  other  hand,
Fig. 2B  depicts  the  appearance  of  centronuclear  myopathy
(i.e., miopatia  centronuclear),  in  which  the  nucleus  assumes
a central  place  in  the  muscle  ﬁber,  while  usually  it  would
occupy a  subsarcolemmal  position,  i.e.,  just  below  the  cyto-
plasmic membrane.11reezing).  (A)  Miopatia  da  parte  central,  or  central  core  myopa-
entral  circular  area  (core);  the  vertical  arrow  depicts  a  ﬁber
ADH.  (B)  Centronuclear  myopathy:  White  arrows  show  ﬁbers
sition  of  the  nucleus,  just  below  the  cytoplasmic  membrane
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